skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Mostrar Somente
Refinado por: assunto: Metformin remover assunto: Type 2 Diabetes remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

Henry, Robert R ; Frias, Juan P ; Walsh, Brandon ; Skare, Sharon ; Hemming, John ; Burns, Colleen ; Bicsak, Thomas A ; Baron, Alain ; Fineman, Mark Samocha-Bonet, Dorit

PloS one, 2018-09, Vol.13 (9), p.e0203946-e0203946 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por
2
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Frias, Juan P ; Bonora, Enzo ; Nevarez Ruiz, Luis ; Li, Ying G ; Yu, Zhuoxin ; Milicevic, Zvonko ; Malik, Raleigh ; Bethel, M Angelyn ; Cox, David A

Diabetes care, 2021-03, Vol.44 (3), p.765-773 [Periódico revisado por pares]

United States: American Diabetes Association

Texto completo disponível

Citações Citado por
3
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Guja, Cristian ; Frías, Juan P. ; Somogyi, Aniko ; Jabbour, Serge ; Wang, Hui ; Hardy, Elise ; Rosenstock, Julio

Diabetes, obesity & metabolism, 2018-07, Vol.20 (7), p.1602-1614

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
4
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Saxena, Aditi R. ; Frias, Juan P. ; Gorman, Donal N. ; Lopez, Rene N. ; Andrawis, Nabil ; Tsamandouras, Nikolaos ; Birnbaum, Morris J.

Diabetes, obesity & metabolism, 2023-10, Vol.25 (10), p.2805-2814

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
5
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

McCrimmon, Rory J. ; Catarig, Andrei-Mircea ; Frias, Juan P. ; Lausvig, Nanna L. ; le Roux, Carel W. ; Thielke, Desirée ; Lingvay, Ildiko

Diabetologia, 2020-03, Vol.63 (3), p.473-485 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
6
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

Bonora, Enzo ; Frias, Juan P. ; Tinahones, Francisco J. ; Van, Joanna ; Malik, Raleigh E. ; Yu, Zhuoxin ; Mody, Reema ; Bethel, Angelyn ; Kwan, Anita Y. M. ; Cox, David A.

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2242-2250

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study

Jabbour, Serge A. ; Frías, Juan P. ; Guja, Cristian ; Hardy, Elise ; Ahmed, Azazuddin ; Öhman, Peter

Diabetes, obesity & metabolism, 2018-06, Vol.20 (6), p.1515-1519

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
8
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo‐controlled trial in patients with type 2 diabetes using metformin

Frias, Juan P. ; Wynne, Alan G. ; Matyjaszek‐Matuszek, Beata ; Bartaskova, Dagmar ; Cox, David A. ; Woodward, Brad ; Li, Ying G. ; Tham, Lai S. ; Milicevic, Zvonko

Diabetes, obesity & metabolism, 2019-09, Vol.21 (9), p.2048-2057

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
9
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial

Frías, Juan P. ; Hardy, Elise ; Ahmed, Azazuddin ; Öhman, Peter ; Jabbour, Serge ; Wang, Hui ; Guja, Cristian

Diabetes, obesity & metabolism, 2018-06, Vol.20 (6), p.1520-1525

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Frías, Juan P. ; Maaske, Jill ; Suchower, Lisa ; Johansson, Lars ; Hockings, Paul D. ; Iqbal, Nayyar ; Wilding, John P. H.

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.61-71

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (3)

Data de Publicação 

De até
Refinar
  1. Antes de2018  (1)
  2. 2018Até2018  (4)
  3. 2019Até2019  (2)
  4. 2020Até2021  (4)
  5. Após 2021  (2)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.